Panel votes to delay Medicaid coverage decision on GLP‑1 obesity drugs, 4–2

The House Commerce & Consumer Affairs subcommittee on Tuesday voted 4–2 to mark Senate Bill 455 — which would clarify Medicaid coverage for GLP‑1 obesity medications — Inexpedient to Legislate, effectively halting near‑term passage.

Members airing concerns said the state and insurers need more data on long‑term use, maintenance dosing, potential lifetime therapy and budget implications before codifying Medicaid coverage. In discussion, members weighed testimony that monthly costs can reach more than $1,200 for some commercial plans and stressed the need to define clinical eligibility and stopping rules.

Representative Purcelli framed her objection to immediate passage in clinical and market terms: "I respectfully disagree. I understand that we've got an obesity epidemic in this country, but I'm... very concerned that... we increasing these medications where there may be no end point. We're not sure what the long‑term effects are." Representative Thaxton also said he would vote to ITL and expected the bill to return next year with more data. The motion to find the bill Inexpedient to Legislate carried 4–2.

Members noted the governor’s stated unwillingness to fund an expansion and said that, regardless of committee disposition, the executive branch’s position would shape outcomes. The subcommittee left the door open for interim study and further data collection before future consideration.

What’s next: The committee’s ITL recommendation removes the bill from immediate consideration; sponsors and stakeholders said they will continue to gather long‑term outcomes and cost data for future sessions.